Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
Biotech’s propensity to manipulate clinical datasets to show significance where none exists must be curbed, but a plan to raise the p value threshold looks like a way of…
Public criticism fails to derail approval of Acelrx’s opioid painkiller, but not without a lengthy apologia from Scott Gottlieb.
Medicare is to review ways to encourage use of non-addictive pain relievers, but Heron Therapeutics will miss out on extension of a special payment provision.
Companies like Nanjing Legend and Cellular Biomedicine Group continue to attract major financial endorsement from Western big pharma, but the threat of scandal is…
Private price negotiation is a hallmark of the US health care system – banning rebates does not make that any less true.
Government document seeks comment on scheme for physician-administered drugs.
Drug price inflation has slowed to crawl, but political pressure can only keep a lid on costs for so long.
Questions about hallucination and deaths continue to swirl around Acadia's Nuplazid.